Citations 3
Medical, Societal, and Ethical Considerations for Directed Blood Donation in 2025
Jacobs, Jeremy W. , Lewis‐Newby, Mithya , Saifee, Nabiha H. , Ferguson, Eamonn , Cohn, Claudia S. , Delaney, Meghan , Morley, Sarah L. , Thomas, Stephen , Thorpe, Rachel , Raza, Sheharyar , Weaver, Meaghann S. , Sharma, Deva , So‐Osman, Cynthia , Yurtsever, Nalan , Fasano, Ross M. , Erikstrup, Christian , Infanti, Laura , Schlafer, Timothy D., Bloch, Evan M. , Booth, Garrett , Lewis-Newby, Mithya , Saifee, Nabiha H , Ferguson, Eamonn , Cohn, Claudia S , Delaney, Meghan , Morley, Sarah , Thomas, Stephen , Thorpe, Rachel , Woo, Jennifer S , So-Osman, Cynthia , Yurtsever, Nalan , Tormey, Christopher A , Waters, Allison , Goldman, Mindy , Yan, Matthew T S , Stephens, Laura , Allen, Elizabeth S , Erikstrup, Christian , Infanti, Laura , Warner, Matthew A , Winters, Jeffrey L , Tobian, Aaron A R , Bloch, Evan M , Jacobs, Jeremy W , Booth, Garrett S. , Woo, Jennifer S. , Tormey, Christopher A. , Stephens, Laura D. , Allen, Elizabeth S. , Warner, Matthew A. , Winters, Jeffrey L. , Tobian, Aaron A.R.
Annals of Internal Medicine | May 12, 2025 | Volume: 178 | Issue: 7 | Pages: 1021-1026
A global analysis of the use of immunoglobulin, shortages in supply, and mitigating measures: A survey of hospital providers (a BEST Collaborative study)
So‐Osman, Cynthia , Delaney, Meghan , Murphy, Michael , Sasongko, Praiseldy Langi , Tinmouth, Alan , Collaborative, the Best ImmunoGlobulin (BIG) Study Group* the Biomedical Excellence for Safer Transfusion, Fung, Mark K , Lu, Wen , Murphy, Michael , Sasongko, Praiseldy Langi , Tiberghien, Pierre , Collaborative, the Best ImmunoGlobulin (BIG) Study Group* the Biomedical Excellence for Safer Transfusion
Transfusion | March 22, 2024 | Volume: 64 | Issue: 5 | Pages: 775-783
AbstractBackgroundImmunoglobulin (IG) therapy is widely used to treat primary and secondary immune deficiencies and as immunomodulatory agent for various disorders. There is great concern that shortages of IG may rise, potentially affecting medical treatment options.Study Design and MethodsAn international survey was developed to study how intravenous immunoglobulins (IVIGs) are used and managed within hospitals in case of shortages. Study data were collected and managed using REDCap electronic data capture tools hosted by the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. The survey was directed to hospital pharmacists and blood bank transfusion professionals and disseminated through members of the BEST Collaborative network.ResultsSurvey respondents from institutions in the USA, Canada, Europe, Japan, and Australia (n = 13) confirmed that the primary specialties utilizing IG are neurology, hematology, and immunology. More than 60% of respondents reported IG supply shortages, but mitigation strategies were not well developed.DiscussionAs IG is the leading driver in plasma demand, more studies are needed to understand current and future demand for IG from the clinical perspective. Necessity lies in establishing clinical guidance to address shortages.
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Bloch, Evan M. , Shoham, Shmuel , Senefeld, Jonathon W. , Baden, Lindsey R. , So‐Osman, Cynthia , Razonable, Raymund R. , Joyner, Michael J. , Shoham, Shmuel , Senefeld, Jonathon, Razonable, Raymund R , Casadevall, Arturo , Avery, Robin K , Joyner, Michael J , Senefeld, Jonathon W , Focosi, Daniele , Tobian, Aaron A.R. , Tiberghien, Pierre , Sullivan, David , Cohn, Claudia S. , Dioverti, M. Veronica , Henderson, Jeffrey P. , Juskewitch, Justin E. , Franchini, Massimo , Goel, Ruchika , Grossman, Brenda J. , Casadevall, Arturo , Pirofski, Liise‐anne , Gebo, Kelly A
Clinical Infectious Diseases | February 6, 2023 | Volume: 76 | Issue: 11 | Pages: 2018-2024
Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.